CTI BioPharma Corp. (NASDAQ:CTIC) Receives $9.21 Consensus PT from Analysts

Shares of CTI BioPharma Corp. (NASDAQ:CTICGet Rating) have been given an average recommendation of “Buy” by the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $9.21.

Several equities research analysts have issued reports on CTIC shares. StockNews.com started coverage on CTI BioPharma in a research note on Thursday, March 31st. They set a “sell” rating for the company. Brookline Capital Management lifted their price target on CTI BioPharma from $7.20 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, March 1st. Needham & Company LLC lifted their price objective on CTI BioPharma from $5.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, March 2nd. Brookline Capital Acquisition lifted their price objective on CTI BioPharma from $7.20 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, March 1st. Finally, JMP Securities lifted their price objective on CTI BioPharma from $4.00 to $5.00 and gave the stock a “market outperform” rating in a report on Wednesday, March 2nd.

NASDAQ:CTIC traded down $0.26 during trading hours on Wednesday, hitting $4.61. 2,475,074 shares of the company’s stock traded hands, compared to its average volume of 4,798,783. The company has a market cap of $460.62 million, a price-to-earnings ratio of -4.08 and a beta of 1.11. CTI BioPharma has a 52 week low of $1.43 and a 52 week high of $5.25. The company has a fifty day moving average of $3.52.

CTI BioPharma (NASDAQ:CTICGet Rating) last posted its quarterly earnings data on Thursday, March 31st. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.10). Analysts anticipate that CTI BioPharma will post -0.31 EPS for the current year.

Large investors have recently made changes to their positions in the stock. Northern Trust Corp grew its position in shares of CTI BioPharma by 7.5% in the 4th quarter. Northern Trust Corp now owns 135,693 shares of the biopharmaceutical company’s stock worth $337,000 after buying an additional 9,434 shares during the period. Qube Research & Technologies Ltd grew its position in shares of CTI BioPharma by 52.4% in the 4th quarter. Qube Research & Technologies Ltd now owns 37,626 shares of the biopharmaceutical company’s stock worth $93,000 after buying an additional 12,938 shares during the period. Jane Street Group LLC purchased a new stake in shares of CTI BioPharma in the 3rd quarter worth about $51,000. Barclays PLC grew its position in shares of CTI BioPharma by 365.8% in the 3rd quarter. Barclays PLC now owns 26,108 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 20,503 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of CTI BioPharma by 3.6% in the 4th quarter. Geode Capital Management LLC now owns 682,626 shares of the biopharmaceutical company’s stock worth $1,692,000 after buying an additional 23,800 shares during the period. Institutional investors own 52.27% of the company’s stock.

CTI BioPharma Company Profile (Get Rating)

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis.

Featured Articles

Analyst Recommendations for CTI BioPharma (NASDAQ:CTIC)

Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.